Canaccord lowered the firm’s price target on Omada Health (OMDA) to $22 from $28 and keeps a Buy rating on the shares. The firm updated its model following strong Q4 results and said the quarter and full-year results demonstrate continued momentum, with robust growth across all programs. Omada is proving that it’s not just a beneficiary of a rapidly evolving GLP-1 market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA: